HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tobias Peinhaupt Selected Research

pembrolizumab

5/2023Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tobias Peinhaupt Research Topics

Disease

1Melanoma (Melanoma, Malignant)
05/2023
1Skin Neoplasms (Skin Cancer)
05/2023

Drug/Important Bio-Agent (IBA)

1pembrolizumabIBA
05/2023
1NivolumabIBA
05/2023
1AntibodiesIBA
05/2023

Therapy/Procedure

1Therapeutics
05/2023